SCYNEXIS, Inc. SCYX
At closeNov 3, 2026, 4:10 PM EST
After hours · Nov 3, 4:10 PM ET
- YTD
- -22.13%
- 1 year
- -22.90%
- Market cap
- 39.20M
- Revenue (ttm)
- 8.57M
- EPS (ttm)
- -0.89
- Shares out
- 37.94M
- Forward P/E
- 6.80
- YTD return
- -22.13%
- 1-year return
- -22.90%
- Volume
- 51.98K
- Avg volume
- 228.36K
- Open
- 3.81
- Previous close
- 3.81
- Day's range
- 3.81 – 3.98
- 52-week range
- 3.53 – 9.12
- Beta
- 1.50
- Analysts
- Strong Buy
- Price target
- 6.67 (+69.2%)
1D +0.10 (+2.62%)
Key statistics
- Enterprise value
- -14.98M
- PEG ratio
- 0.00
- Price / sales
- 4.52
- Price / book
- 0.66
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -62.50%
- Free cash flow
- -5.37M
- Total cash
- 68.83M
- Total debt
- 15.90M
- Return on equity
- -48.42%
- Short % of float
- 2.77%
- 50-day average
- 1.30
- 200-day average
- 1.67
Analyst view
Consensus: strong buy
- Target (low)
- 6.00
- Target (mean)
- 6.67
- Target (high)
- 8.00
- Strong buy1
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.065.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -0.20 | -0.06 | +0.14 | +70.00% |
| Aug 8, 2024 | Jun 1, 2024 | -0.19 | -0.30 | -0.11 | -57.89% |
| May 8, 2024 | Mar 1, 2024 | -0.18 | -0.15 | +0.03 | +16.67% |
| Mar 28, 2024 | Dec 1, 2023 | 0.31 | -0.39 | -0.70 | -225.81% |
| Nov 13, 2023 | Sep 1, 2023 | 0.29 | -0.04 | -0.33 | -113.79% |
| Aug 14, 2023 | Jun 1, 2023 | 1.03 | 2.46 | +1.43 | +138.83% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 1, 2024 | Cantor Fitzgerald | reit | — | Overweight |
| Aug 15, 2023 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Apr 3, 2023 | Guggenheim | main | — | Buy |
| Apr 3, 2023 | Ladenburg Thalmann | reit | — | Buy |
| Mar 1, 2023 | Guggenheim | init | — | Buy |
| May 13, 2022 | HC Wainwright & Co. | main | — | Buy |
About SCYNEXIS, Inc.
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- scynexis.com
News
SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference 
SCYNEXIS Announces Its Phase 1 Trial Of Intravenous Formulation Of SCY-247 To Treat Invasive Fungal Infections Showed Intravenous Doses Of 50 Mg Or Higher Achieved Exposures At Or Above Target Identified In Murine Models Of Invasive Candidiasis 
SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases 
SCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek 
SCYNEXIS (NASDAQ:SCYX) Stock Price Crosses Above Fifty Day Moving Average – Time to Sell? 
SCYNEXIS Completes Phase 1 Study Of SCY-770, Selective And Direct AMP-Activated Protein Kinase Activator 
SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) 
Head-To-Head Survey: Amarin (NASDAQ:AMRN) and SCYNEXIS (NASDAQ:SCYX) 
SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247 
Adherex Technologies (NASDAQ:FENC) and SCYNEXIS (NASDAQ:SCYX) Financial Survey
Your note
Sign in to keep a note on SCYX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANGULO GONZALEZ DAVID | Chief Executive Officer | Purchase | Sep 11, 2024 | 507,871 |
| ANIDO ARMANDO | Director | Stock Award(Grant) | Jun 19, 2024 | 48,000 |
| GILMAN STEVEN C | Director | Stock Award(Grant) | Jun 19, 2024 | 47,000 |
| HANHAM ANN F | Director | Stock Award(Grant) | Jun 19, 2024 | 46,622 |
| HASTINGS DAVID C | Director | Stock Award(Grant) | Jun 19, 2024 | 46,183 |
| MACDONALD GUY | Director | Stock Award(Grant) | Jun 19, 2024 | 55,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Federated Hermes, Inc. | 9.47% | 3,595,000 | 3.67M | Sep 29, 2024 |
| Kingdon Capital Management LLC | 5.89% | 2,237,048 | 2.28M | Sep 29, 2024 |
| Vanguard Group Inc | 4.45% | 1,686,967 | 1.72M | Sep 29, 2024 |
| Avidity Partners Management, LP | 3.82% | 1,448,728 | 1.48M | Sep 29, 2024 |
| AMH Equity Ltd. | 1.58% | 600,000 | 612.00K | Sep 29, 2024 |
| Acadian Asset Management. LLC | 1.42% | 540,683 | 551.50K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Federated Hermes Kaufmann Small Cap Fund | 7.91% | 3,003,000 | 3.06M | Jul 30, 2024 |
| Federated Hermes Kaufmann Fund | 3.11% | 1,180,000 | 1.20M | Jul 30, 2024 |
| Vanguard Total Stock Market Index Fund | 3.08% | 1,169,372 | 1.19M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.26% | 479,862 | 489.46K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.57% | 216,085 | 220.41K | Oct 30, 2024 |
| Bridgeway Fds Inc-Omni Small Cap Value Fund | 0.49% | 186,000 | 189.72K | Sep 29, 2024 |